The effect of cumin supplementation on metabolic profiles in patients with metabolic syndrome: A randomized, triple blind, placebo‐controlled clinical trial

2019 ◽  
Vol 33 (4) ◽  
pp. 1182-1190 ◽  
Author(s):  
Ashti Morovati ◽  
Bahram Pourghassem Gargari ◽  
Parvin Sarbakhsh ◽  
Hushyar Azari ◽  
Lida Lotfi‐Dizaji
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Metabolic Profiles

scholarly journals No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial

2017 ◽  
Vol 102 (5) ◽  
pp. 1642-1651 ◽  
Author(s):  
Thomas Nordstrøm Kjær ◽  
Marie Juul Ornstrup ◽  
Morten Møller Poulsen ◽  
Hans Stødkilde-Jørgensen ◽  
Niels Jessen ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Beneficial Effects ◽  
The Metabolic Syndrome

Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults ≥ 55 Years Old. A Study Protocol for a Double-Blinded Randomized Controlled Clinical Trial

2022 ◽  
pp. 1-12
Author(s):  
K.I. Avgerinos ◽  
R.J. Mullins ◽  
J.M. Egan ◽  
D. Kapogiannis
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Cognitive Performance ◽  
Animal Studies ◽  
Brain Metabolism ◽  
Ketone Bodies ◽  
Controlled Clinical Trial ◽  
Resonance Spectroscopy ◽  
Double Blinded ◽  
Cognitively Intact

BACKGROUND: Ketone bodies have been proposed as an “energy rescue” for the Alzheimer’s disease (AD) brain, which underutilizes glucose. Prior research has shown that oral ketone monoester (KME) safely induces robust ketosis in humans and has demonstrated cognitive-enhancing and pathology-reducing properties in animal models of AD. However, human evidence that KME may enhance brain ketone metabolism, improve cognitive performance and engage AD pathogenic cascades is scarce. Objectives: To investigate the effects of ketone monoester (KME) on brain metabolism, cognitive performance and AD pathogenic cascades in cognitively normal older adults with metabolic syndrome and therefore at higher risk for AD. Design: Double-blinded randomized placebo-controlled clinical trial. Setting: Clinical Unit of the National Institute on Aging, Baltimore, US. Participants: Fifty cognitively intact adults ≥ 55 years old, with metabolic syndrome. Intervention: Drinks containing 25 g of KME or isocaloric placebo consumed three times daily for 28 days. Outcomes: Primary: concentration of beta-hydroxybutyrate (BHB) in precuneus measured with Magnetic Resonance Spectroscopy (MRS). Exploratory: plasma and urine BHB, multiple brain and muscle metabolites detected with MRS, cognition assessed with the PACC and NIH toolbox, biomarkers of AD and metabolic mediators in plasma extracellular vesicles, and stool microbiome. Discussion: This is the first study to investigate the AD-biomarker and cognitive effects of KME in humans. Ketone monoester is safe, tolerable, induces robust ketosis, and animal studies indicate that it can modify AD pathology. By conducting a study of KME in a population at risk for AD, we hope to bridge the existing gap between pre-clinical evidence and the potential for brain-metabolic, pro-cognitive, and anti-Alzheimer’s effects in humans.

Effects of Periodontal Therapy on Systemic Markers of Inflammation in Patients With Metabolic Syndrome: A Controlled Clinical Trial

2012 ◽  
Vol 83 (3) ◽  
pp. 267-278 ◽  
Author(s):  
Néstor J. López ◽  
Antonio Quintero ◽  
Patricia A. Casanova ◽  
Carola I. Ibieta ◽  
Vibeke Baelum ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Periodontal Therapy ◽  
Controlled Clinical Trial ◽  
Markers Of Inflammation

scholarly journals Blueberries Improve Endothelial Function, but Not Blood Pressure, in Adults with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Nutrients ◽  
2015 ◽  
Vol 7 (6) ◽  
pp. 4107-4123 ◽  
Author(s):  
April Stull ◽  
Katherine Cash ◽  
Catherine Champagne ◽  
Alok Gupta ◽  
Raymond Boston ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Endothelial Function ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effect of Keishibukuryogan on Endothelial Function in Patients with at Least One Component of the Diagnostic Criteria for Metabolic Syndrome: A Controlled Clinical Trial with Crossover Design

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Yutaka Nagata ◽  
Hirozo Goto ◽  
Hiroaki Hikiami ◽  
Tatsuya Nogami ◽  
Makoto Fujimoto ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Endothelial Function ◽  
Reactive Hyperemia ◽  
Control Period ◽  
Crossover Design ◽  
Controlled Clinical Trial ◽  
Related Factors ◽  
Group A ◽  
Group B

We evaluated the effect of keishibukuryogan (KBG; Guizhi-Fuling-Wan), a traditional Japanese (Kampo) formula, on endothelial function assessed by reactive hyperemia peripheral arterial tonometry (Endo-PAT2000) in patients with metabolic syndrome-related factors by controlled clinical trial with crossover design. Ninety-two patients were assigned to group A (first KBG-treatment period, then control period; each lasting 4 weeks, with about one-year interval) or group B (first control, then KBG-treatment). In forty-nine (27, group A; 22, group B) patients completing all tests, the mean value of the natural logarithmic-scaled reactive hyperemia index (L_RHI) increased and those of serum nonesterified fatty acid (NEFA), malondialdehyde, and soluble vascular cell adhesion molecule 1 decreased significantly during the KBG-treatment period, but not during the control period, and 4-week changes of L_RHI, NEFA, and malondialdehyde between the 2 periods showed significance. These results suggest that KBG has beneficial effect on endothelial function in patients with metabolic syndrome-related factors.

Oral Magnesium Supplementation and Metabolic Syndrome: A Randomized Double-Blind Placebo-Controlled Clinical Trial

2018 ◽  
Vol 25 (3) ◽  
pp. 261-266 ◽  
Author(s):  
Martha Rodríguez-Morán ◽  
Luis E. Simental-Mendía ◽  
Claudia I. Gamboa-Gómez ◽  
Fernando Guerrero-Romero
Keyword(s):  
Metabolic Syndrome ◽  
Clinical Trial ◽  
Controlled Clinical Trial ◽  
Magnesium Supplementation ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Magnesium
Sign in / Sign up

Export Citation Format

Share Document